StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report report published on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 8.7 %
AKTX opened at $1.25 on Monday. The business’s 50-day simple moving average is $1.34 and its 200-day simple moving average is $2.56. Akari Therapeutics has a one year low of $0.90 and a one year high of $4.40.
Akari Therapeutics Company Profile
Recommended Stories
- Five stocks we like better than Akari Therapeutics
- What is the Hang Seng index?
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- 3 REITs to Buy and Hold for the Long Term
- How Do Stock Buybacks Affect Shareholders?
- Following Congress Stock Trades
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.